Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital

Infections With CPB Clinical Trial

— CPB-Epi Basel  

Official title:

Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04098133
• Other study ID #: 2019-01548; me19Tschudinsutter
• Status: Recruiting
• Start date: August 22, 2019
• Est. completion date: June 30, 2029

Study information

• Verified date: September 2023
• Source: University Hospital, Basel, Switzerland
• Contact: Sarah Tschudin Sutter, Prof. Dr. MD
• Phone: +41 61 328 68 10
• Email: sarah.tschudin[@]usb.ch
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This retrospective and prospective study is to investigate the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel, the time to detection of CPB and to initiation of infection control measures, the risk factors associated with carriage of CPB, type and duration of previously administrated antibiotic medication, antibiotic treatment, as well as to assess the outcomes of the affected patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 30, 2029
• Est. primary completion date: June 30, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with detection of carbapenemase-producing bacteria from January 1st , 2008 until December 31st , 2028

Exclusion Criteria:

• Patients with documented refusal of subsequent use of their data

Related Conditions & MeSH terms

• Infections
• Infections With CPB

Intervention

Other:
• data collection for demographic data
data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
• data collection for clinical data
data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
• data collection for treatment data
data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
• data collection for microbiological data
data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)

Locations

Country	Name	City	State
Switzerland	Division of Infectious Diseases and Hospital Epidemiology	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	incidence of CPB at the University Hospital Basel (number)	incidence of CPB at the University Hospital Basel (number)	from January 1st , 2008 until December 31st, 2028
Secondary	time to detection of CPB (days)	time to detection of CPB (days)	from January 1st , 2008 until December 31st, 2028
Secondary	time to initiation of infection control measures	time to initiation of infection control measures	from January 1st , 2008 until December 31st, 2028
Secondary	time to adequate treatment in patients with CPB infections	time to adequate treatment in patients with CPB infections	from January 1st , 2008 until December 31st, 2028
Secondary	presence of established risk factors for CPB	presence of established risk factors for CPB	from January 1st , 2008 until December 31st, 2028
Secondary	length of hospital stay (days)	length of hospital stay (days)	from January 1st , 2008 until December 31st, 2028
Secondary	discharge destination	discharge destination	from January 1st , 2008 until December 31st, 2028
Secondary	cure from infection	cure from infection	from January 1st , 2008 until December 31st, 2028
Secondary	cause-specific mortality (number)	cause-specific mortality (number)	from January 1st , 2008 until December 31st, 2028
Secondary	all-cause mortality (number)	all-cause mortality (number)	from January 1st , 2008 until December 31st, 2028